Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | The impact of tafasitamab on the efficacy and safety of CD19 CAR-T therapy in preclinical models

Reona Sakemura • 2 May 2023
EBMT 2023
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Lenalidomide Tafasitamab

Reona Sakemura, MD, PhD, Mayo Clinic, Rochester, MN, shares the results of a study that investigated the interactions between tafasitamab and CD19 CAR-T therapy in preclinical models. It was found that transient CD19 masking induced by tafasitamab reduces CD19 CAR-T therapy apoptosis and tumor pyroptosis, resulting in an increased therapeutic index of the CAR-T therapy in preclinical models. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Humanigen – patent, Morphosys – travel fund

More from Reona Sakemura

3:03
Using dual-targeting CAR-Ts to overcome CAF-induced CAR-T resistance in multiple myeloma
Reona Sakemura • 24 Apr 2022
1:31
Impact of prior tafasitamab treatment on subsequent CD19-directed CAR-T therapy
Reona Sakemura • 24 Apr 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals